Use of HeberFERON® in an HIV/AIDS patient with basal cell carcinoma
Abstract
Introduction: basal cell carcinoma is a malignant neoplasm of the lining epithelium. Its appearance is closely linked to exposure to sunlight. Although it constitutes 60 % of skin tumors, it is considered a malignant neoplasm with a good prognosis.
Objective: to present the case of an HIV/AIDS patient with facial basal cell carcinoma treated with HeberFERON®.
Case presentation: a 70-year-old white male patient who attended the maxillofacial surgery consultation in February 2016 to remove a three-year-old lesion on the nose. He had a history of high blood pressure, had been an HIV carrier for 16 years and had undergone surgery on five occasions for presenting basal cell carcinomas of the face. He refused surgical treatment due to complications from previous operations. For this reason, treatment with HeberFERON® was suggested, an option that he accepted. After four years, during the consultation to verify the evolution of the disease, the patient was cured and expressed his satisfaction with the procedure.
Conclusions:with the use of HeberFERON®, complete regression of the facial basal cell carcinoma that he suffered was achieved in this patient, and the performance of a non-consensual surgical act was avoided. The treatment had excellent oncological, aesthetic and psychological results, with minimal complications. The contribution of this work lies in highlighting the option of drug treatment with HeberFERON® in those cases in which patients with basal cell carcinoma do not consent to surgical intervention, with excellent results in an immunodeficient patient.
Downloads
Published
How to Cite
Issue
Section
License
MediCiego does not apply publication charges. The journal is available in open access without restrictions, in compliance with the international policy on open access to information for the exchange of global knowledge.
The authors will retain their copyright and guarantee the journal the right of first publication of their work. MediCiego is licensed under the Creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/deed.es_ES), so it is allowed to copy, reproduce, distribute, publicly communicate the work and generate derivative works, as long as the original author is cited and acknowledged. However, it is not allowed to use the original work for commercial or lucrative purposes.
Authors must sign a copyright agreement through an affidavit of authorship and originality, before publishing.
The authors authorize the publication of their writings; they retain the copyright, and assign to the journal all the rights protected by the Copyright Law that governs Cuba, and implies the edition to disseminate the work.
Likewise, they may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with the recognition of having been first published in this journal.
Declaration of authorship: download here the Affidavit
